NCT00765076已完成3 期
Observer-blind Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2186877A in Elderly Subjects
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 192
- 试验地点
- 5
- 主要终点
- The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains Which Are Producing at Least Two Different Markers
研究概览
简要总结
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
详细描述
The amendment to the protocol posting: minor change in one inclusion criterion and in one secondary outcome measure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All subjects must satisfy the following criteria at study entry:
- •Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. Specific attention should be given to the compliance potential of subjects with suspected or known drug or alcohol abuse.
- •Written informed consent obtained from the subject.
- •Free of an acute aggravation of the health status as established by medical history and clinical examination before entering into the study.
- •Elderly adults:
- •A man or woman 65 year of age or older at the time of the first vaccination.
- •Young adults:
- •Man or woman between the ages of 18 and 40 years, inclusive.
- •If the subject is female, she must be of non-childbearing potential or be post-menopausal, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after vaccination.
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period.
- •Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to Visit 4 after vaccination and of an influenza vaccine other than the study vaccines up to Visit
- •Vaccination against influenza since February 2008 with a seasonal influenza vaccine.
- •Previous vaccination in the last three years with an investigational adjuvanted vaccine candidate seasonal or pandemic influenza vaccine.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •History of hypersensivity to a previous dose of influenza vaccine.
- •History of allergy or reactions likely to be exacerbated by any component of the vaccine(s) including egg or chicken protein.
- •Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation or pre-existing laboratory screening tests.
- •Acute disease at the time of enrolment.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study.
- •Any medical conditions in which intramuscular injections are contraindicated.
- •Pregnant or lactating female.
- •Female of childbearing age planning to become pregnant or planning to discontinue contraceptive precautions.
- •Any medical condition that in the opinion of the investigator precludes the collection of blood volumes as required by the protocol.
结局指标
主要结局
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains Which Are Producing at Least Two Different Markers
时间窗: Day 21
The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ)
次要结局
- The Number of Subjects Seroprotected to HI Antibodies(At Day 0, 21, 42 and 180)
- Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs)(Day 0-179)
- The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers(At Day 0, 21, 42 and 180)
- The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker(At Day 0, 21, 42 and 180)
- Haemagglutinin Inhibition (HI) Antibody Titers(At Day 0, 21, 42 and 180)
- The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains.(At Day 0, 21, 42 and 180)
- The Number of Subjects Seroconverted to HI Antibodies(At Day 21, 42 and 180)
- Duration of Solicited General AEs(Day 0 -6)
- Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs(Day 0-20)
- HI Antibody Seroconversion Factors(At Day 21, 42 and 180)
- Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs(Day 0 -6)
- Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)(Day 0 -6)
- Duration of Solicited Local AEs(Day 0 -6)
- Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)(Day 0-364)
- Number of Subjects Reporting Any AEs of Specific Interest (AESI)(Day 0-364)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly PeopleInfluenzaNCT00992784GlaxoSmithKline370
已完成
2 期
Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and OverInfluenzaNCT00532298GlaxoSmithKline1,596
撤回
3 期
A Study for Evaluation of GSK Biologicals' Pandemic Influenza VaccineInfluenzaNCT00866580GlaxoSmithKline
已完成
3 期
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in ChildrenInfluenzaNCT01198756GlaxoSmithKline3,109
已完成
2 期
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 YearsInfluenzaNCT00771615GlaxoSmithKline469